CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 300 enrolled
Drug / intervention
Reproxalap Ophthalmic Solution (0.25%) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03404115
NCT03404115Phase 2Completed
CompareCT.gov

A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease

Aldeyra Therapeutics, Inc.·interventional·Posted Jan 19, 2018·Updated Feb 6, 2025

In Brief

A Phase 2 clinical trial evaluating Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), and 1 other intervention for Dry Eye Syndrome. Completed, enrolled 300 participants across 6 sites.

Detailed Summary

A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects with Dry Eye Disease

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 19, 2018
Enrollment StartJan 2, 2018
Primary CompletionJul 11, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.5 years ago

Interventions

Reproxalap Ophthalmic Solution (0.25%)drug

Reproxalap Ophthalmic Solution (0.25%) administered for approximately twelve weeks.

Reproxalap Ophthalmic Solution (0.1%)drug

Reproxalap Ophthalmic Solution (0.1%) administered for approximately twelve weeks.

Vehicle Ophthalmic Solutiondrug

Vehicle Ophthalmic Solution administered for approximately twelve weeks.